<DOC>
	<DOCNO>NCT02782104</DOCNO>
	<brief_summary>The purpose study assess safety tolerability intranasal esketamine participant treatment-resistant depression ( TRD ) .</brief_summary>
	<brief_title>A Long-term Safety Study Intranasal Esketamine Treatment-resistant Depression</brief_title>
	<detailed_description>This open-label ( researcher participant know treatment participant receive ) long-term extension study . The study consist 2 open-label Phases : 4-week Induction phase ( applicable ) Open-Label Optimization/Maintenance phase ( variable ) . Participants enter study Induction Phase ESKETINTRD3001 ( NCT02417064 ) , ESKETINTRD3002 ( NCT02418585 ) , ESKETINTRD3003 ( NCT02493868 ) , ESKETINTRD3005 ( NCT02422186 ) ESKETINTRD3006 ( US sit ) . Participants enter study Open-Label Optimization/Maintenance phase ESKETINTRD3001 ( NCT02417064 ) , ESKETINTRD3002 ( NCT02418585 ) , ESKETINTRD3003 ( NCT02493868 ) ( appropriate week 16 ) ESKETINTRD3006 ( US sit ) . In Open-Label Induction Phase , participants self-administer flexibly-dosed intranasal esketamine . During first 4 week Optimization/Maintenance Phase responder participant induction phase study 54135419TRD3008 , continue dose intranasal esketamine induction phase weekly intranasal treatment session frequency . Participants enter optimization/maintenance phase study ESKETINTRD3005 also weekly intranasal treatment session frequency . However , ESKETINTRD3005 intranasal study medication blind time entry current study , dose intranasal esketamine administer outline protocol . Participants enter optimization/maintenance phase study ESKETINTRD3003 ( Direct Entry ) ESKETINTRD3004 ongoing Optimization , Maintenance , Optimization/Maintenance phase , respectively , option current intranasal dose frequency adjust time entry 54135419TRD3008 study remain select frequency week 1 week 4 . A one-time dose change permit study entry . After 4 week , intranasal esketamine treatment session individualize either weekly every week base severity depressive symptom . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>Based prior study participant enter 54135419TRD3008 : ) From ESKETINTRD3001 ( NCT02417064 ) ESKETINTRD3002 ( NCT02418585 ) study : Participant complete induction phase 2weeks follow phase visit ; Participants complete induction phase responder study ESKETINTRD3003 terminate . ; b ) From ESKETINTRD3003 ( NCT02493868 ) study : ( 1 ) Participant relapse maintenance phase ; ( 2 ) Participant induction phase ESKETINTRD3003 study study terminate , completion induction phase , determine responder ; ( 3 ) Participant optimization maintenance phase time study terminate ; ( 4 ) ( 5 ) Participants induction phase completion induction phase determine meet response criterion ( 1 ) Participant complete ESKETINTRD3004 study ( optimization/maintenance phase ) ; ( 2 ) Participant induction phase ESKETINTRD3004 study study terminate , completion induction phase , determine responder ; ( 3 ) Participant optimization/maintenance phase time study terminate ; ( 4 ) Participant induction phase meet criterion response may eligible roll 54135419TRD3008 . ) From ESKETINTRD3005 ( NCT02422186 ) study : Participant induction phase ESKETINTRD3005 study time enrollment ESKETINTRD3004 study close , completion induction phase , determine responder meet criterion response . e ) From ESKETINTRD3006 study ( US Study site ) ( 1 ) Participant complete induction phase responder . Participant must medically stable basis physical examination , vital sign , pulse oximetry , 12lead Electrocardiogram ( ECG ) perform predose day first intranasal treatment session . If abnormality specify inclusion exclusion criterion , clinical significance must determine investigator record participant 's source document initial investigator Participant must medically stable accord investigator 's judgment knowledge subject 's medical stability parent study . This determination must document . A woman childbearing potential must negative serum ( betahuman chorionic gonadotropin [ bhCG ] ) predose day first intranasal treatment session During study ( , first intranasal treatment session ) minimum 1 spermatogenesis cycle ( define approximately 90 day ) receive last dose intranasal study medication , man sexually active woman childbearing potential must practice highly effective method contraception female partner c ) must agree donate sperm . The evaluation benefit versus risk continue intranasal esketamine treatment favorable participant opinion investigator Since last study visit participant 's prior study , participant suicidal ideation intent act per investigator 's clinical judgment base Columbia Suicide Severity Rating Scale ( CSSRS ) [ correspond response `` Yes '' Item 4 ( active suicidal ideation intent act , without specific plan ) Item 5 ( active suicidal ideation specific plan intent ) suicidal ideation module CSSRS ] suicidal behavior per investigator 's clinical judgment base CSSRS ( correspond score high 0 suicidal behavior module CSSRS ) Participant positive test result ( ) drug abuse ( include barbiturate , methadone , opiates , cocaine , phencyclidine , amphetamine/methamphetamine ) predose day first intranasal treatment session Participant anatomical medical condition , per investigator 's clinical judgment base assessment , may impede delivery absorption intranasal study drug Participant take prohibited therapy would permit administration first intranasal treatment session</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Depressive Disorder , Treatment-Resistant</keyword>
	<keyword>Esketamine</keyword>
	<keyword>JNJ-54135419</keyword>
</DOC>